Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 1836-1845

  Pchejetski, Dimitri ^a,b,d   Doumerc, Nicolas ^b,c   Golzio, Muriel ^a,b   Naymark, Maria ^d   Teissié, Justin ^a,b   Kohama, Takafumi ^e   Waxman, Jonathan ^d   Malavaud, Bernard ^a,b,c   Cuvillier, Olivier ^a,b,c  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU RANGUEIL   (France)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B 535C; CAMPTOTHECIN; CERAMIDE; DOCETAXEL; IRINOTECAN; PHOSPHOTRANSFERASE INHIBITOR; SPHINGOLIPID; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; 4 AMINOBENZOIC ACID; ANTINEOPLASTIC AGENT; B 5354C; CASPASE; DRUG DERIVATIVE; GREEN FLUORESCENT PROTEIN; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN LNCAP; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; CELL SURVIVAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; METASTASIS; PROSTATE TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

4-AMINOBENZOIC ACID; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; DRUG THERAPY, COMBINATION; GREEN FLUORESCENT PROTEINS; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MICE; NEOPLASM METASTASIS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSTATIC NEOPLASMS; SPHINGOSINE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51049121847     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2322     Document Type: Article

References (37)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
4. Hussain M, Tangen CM, Lara PN, Jr., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-9.
5. Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: results of the CALGB 99901. Urol Oncol 2004;22:398-403.
6. Pchejetski D, Golzio M, Bonhoure E, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005;65:11667-75.
7. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-3.
8. Bonhoure E, Pchejetski D, Aouali N, et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 2006;20:95-102.
9. Johnson KR, Johnson KY, Crellin HG, et al. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 2005;53:1159-66.
10. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005;64:695-705.
11. Kawamori T, Osta W, Johnson KR, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 2006;20:386-8.
12. Cuvillier O. Sphingosine kinase-1 - a potential therapeutic target in cancer. Anticancer Drugs 2007;18:105-10.
13. Kono K, Sugiura M, Kohama T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J Antibiot (Tokyo) 2002;55:99-103.
14. Cuvillier O, Rosenthal DS, Smulson ME, Spiegel S. Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes. J Biol Chem 1998;273:2910-6.
15. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 1998;273:23722-8.
16. Perry DK, Bielawska A, Hannun YA. Quantitative determination of ceramide using diglyceride kinase. Methods Enzymol 2000;312:22-31.
17. Edsall LC, Spiegel S. Enzymatic measurement of sphingosine 1-phosphate. Anal Biochem 1999;272:80-6.
18. Cuvillier O, Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 2001;98:2828-36.
19. Cuvillier O, Mayhew E, Janoff AS, Spiegel S. Liposomal ET-18-OCH(3) induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling. Blood 1999;94:3583-92.
20. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-7.
21. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001;298:865-72.
22. Borner MM, Myers CE, Sartor O, et al. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995;55:2122-8.
23. Arah IN, Song K, Seth P, Cowan KH, Sinha BK. Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Res 1998;18:1845-9.
24. Wang XZ, Beebe JR, Pwiti L, Bielawska A, Smyth MJ. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res 1999;59:5842-8.
25. Costa-Pereira AP, Cotter TG. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 1999;80:371-8.
26. de Souza PL, Cooper MR, Imondi AR, Myers CE. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin Cancer Res 1997;3:287-94.
27. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9.
28. Nava VE, Cuvillier O, Edsall LC, et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 2000;60:4468-74.
29. Taha TA, Osta W, Kozhaya L, et al. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 2004;279:20546-54.
30. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 2002;281:115-27.
31. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B, Spiegel S. N,N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 1998;37:12892-8.
32. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000;92:1897-909.
33. Kono K, Tanaka M, Ogita T, Kohama T. Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot (Tokyo) 2000;53:759-64.
34. Igarashi Y, Hakomori S, Toyokuni T, et al. Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. Biochemistry 1989;28:6796-800.
35. Khan WA, Dobrowsky R, el Touny S, Hannun YA. Protein kinase C and platelet inhibition by D-erythro-sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun 1990;172:683-91.
36. Jarvis WD, Fornari FA, Jr., Tombes RM , et al. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 1998;54:844-56.
37. Endo K, Igarashi Y, Nisar M, Zhou QH, Hakomori S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethyl and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res 1991;51:1613-8.